Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE WOODLANDS, TEXAS, JULY 30, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY WILL RELEASE ITSSECOND QUARTER 2026FINANCIAL RESULTS ONTHURSDAY,AUGUST 6, 2026,PRIOR TOMARKETOPEN. MANAGEMENT WILL CONDUCT A CONFERENCE CALL AND LIVE WEBCAST AT8:30A.M. ET (7:30A.M. CT) THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND TO PROVIDE A BUSINESS UPDATE.

LEXICON PHARMACEUTICALS TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 6, 2026

STUDY SUBSTANTIALLY EXCEEDED ENROLLMENT TARGET OF 500 PATIENTS TOPLINE RESULTS ANTICIPATED IN Q1 2027 THE WOODLANDS, TEXAS, JULY 27, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THAT RANDOMIZATION OF PATIENTS HAS BEEN COMPLETED IN THE PIVOTAL PHASE 3 SOTAGLIFLOZININ PATIENTS WITH SYMPTOMATIC OBSTRUCTIVEAND NON-OBSTRUCTIVEHYPERTROPHICCARDIOMYOPATHY (SONATA-HCM) CLINICAL TRIAL EVALUATING SOTAGLIFLOZIN IN PATIENTS WITH NON-OBSTRUCTIVE (NHCM) AND OBSTRUCTIVE (OHCM) HYPERTROPHIC CARDIOMYOPATHY. THE STUDY SUBSTANTIALLY EXCEEDED ITS ENROLLMENT TARGET OF 500 PATIENTS ACROSS MORE THAN 130 SITES IN 20 COUNTRIES.

LEXICON PHARMACEUTICALS COMPLETES ENROLLMENT OF PIVOTAL PHASE 3 SONATA-HCM STUDY OF SOTAGLIFLOZIN IN SYMPTOMATIC NON-OBSTRUCTIVE AND OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM)

PRESENTATIONS HIGHLIGHT CONSISTENT A1C REDUCTIONS WITH SOTAGLIFLOZIN IN TYPE 1 DIABETES AND PHARMACOKINETICS OF PILAVAPADIN ACROSS RENAL FUNCTION GROUPS PRESENTATIONS HIGHLIGHT CONSISTENT A1C REDUCTIONS WITH SOTAGLIFLOZIN IN TYPE 1 DIABETES AND PHARMACOKINETICS OF PILAVAPADIN ACROSS RENAL FUNCTION GROUPS

LEXICON TO PRESENT DATA AT THE AMERICAN DIABETES ASSOCIATION (ADA) 2026 SCIENTIFIC SESSIONS

THE WOODLANDS, TEXAS, MAY 28, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.(NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 4, 2026 AT 2:00 P.M. ET IN NEW YORK CITY.

LEXICON PHARMACEUTICALS TO PRESENT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

THE WOODLANDS, TEXAS, MAY 12, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC.(NASDAQ: LXRX) TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 4TH ANNUAL H.C. WAINWRIGHT BIOCONNECT INVESTOR CONFERENCE, TAKING PLACE AT THE NASDAQ WORLD HEADQUARTERS IN NEW YORK CITY, ON MAY 19, 2026.

LEXICON PHARMACEUTICALS TO PRESENT AT THE 4TH ANNUAL H.C. WAINWRIGHT BIOCONNECT INVESTOR CONFERENCE

SONATA-HCM ANTICIPATED TO BE FULLY ENROLLED MID-2026 RESUBMISSION OF NDA FOR ZYNQUISTA  IN TYPE 1 DIABETES ANTICIPATED MID-2026 WITH POTENTIAL FOR APPROVAL THIS YEAR CLINICAL DEVELOPMENT OF LX9851 INITIATED BY NOVO NORDISK CAPITAL RAISE, DEVELOPMENT MILESTONE PAYMENTS, AND RECENT $100 MILLION LOAN FACILITY REINFORCE STRONG FINANCIAL POSITION  CONFERENCE CALL AND WEBCAST AT 8:30 AM ET  THE WOODLANDS, TEXAS, MAY 07, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX), TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026, AND PROVIDED AN UPDATE ON KEY CORPORATE MILESTONES AND ACCOMPLISHMENTS. WE HAVE BEEN INTENTLY FOCUSED ON PROGRESSING OUR LATE AND EARLY-STAGE DEVELOPMENT PIPELINE IN CARDIOMETABOLISM AND WE ARE NOW WELL POSITIONED TO ACHIEVE SEVERAL PIVOTAL MILESTONES AS A RESULT OF THOSE EFFORTS, SAID MIKE EXTON, PH.D.

LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES

THE WOODLANDS, TEXAS, MAY 04, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) ANNOUNCED TODAY THAT IT HAS ENTERED INTO A LOAN FACILITY WITH HERCULES CAPITAL, INC. (NYSE: HTGC) THAT PROVIDES UP TO $100 MILLION IN BORROWING CAPACITY. ACCESS TO THIS NON-DILUTIVE CAPITAL PROVIDES LEXICON WITH GREATER FINANCIAL FLEXIBILITY THROUGH BOTH AN EXTENDED INTEREST-ONLY PERIOD AND MATURITY DATE AND THE OPPORTUNITY TO FURTHER STRENGTHEN ITS BALANCE SHEET TO SUPPORT PIVOTAL UPCOMING REGULATORY AND COMMERCIAL MILESTONES.

LEXICON PHARMACEUTICALS ANNOUNCES $100 MILLION LOAN FACILITY WITH HERCULES CAPITAL

THE WOODLANDS, TEXAS, APRIL 30, 2026 (GLOBE NEWSWIRE) -- LEXICON PHARMACEUTICALS, INC. (NASDAQ: LXRX) TODAY ANNOUNCED THE COMPANY WILL RELEASE ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON THURSDAY, MAY 7, 2026, PRIOR TO MARKET OPEN. MANAGEMENT WILL CONDUCT A CONFERENCE CALL AND LIVE WEBCAST AT 8:30 A.M. ET (7:30 A.M. CT) THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND TO PROVIDE A BUSINESS UPDATE.

LEXICON PHARMACEUTICALSTO REPORTFIRST QUARTER2026FINANCIAL RESULTS ONMAY 7, 2026

ORAL PRESENTATION HIGHLIGHTS ADDITIONAL DATA FROM PROGRESS PHASE 2B STUDY OF PILAVAPADIN SUPPORTING SELECTION OF 10MG AS OPTIMAL DOSE FOR PHASE 3 DEVELOPMENT IN DPNP

LEXICON TO PRESENT DATA AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING

ADDITIONAL ANALYSES FROM THE SCORED AND SOTA-P-CARDIA STUDIES PROVIDE FURTHER EVIDENCE OF BENEFITS ACROSS PATIENT SUBGROUPS POTENTIALLY RELATED TO SOTAGLIFLOZIN'S MECHANISM OF ACTION ADDITIONAL ANALYSES FROM THE SCORED AND SOTA-P-CARDIA STUDIES PROVIDE FURTHER EVIDENCE OF BENEFITS ACROSS PATIENT SUBGROUPS POTENTIALLY RELATED TO SOTAGLIFLOZIN'S MECHANISM OF ACTION

Lexicon Pharmaceuticals, Inc.

LXRX

Price

Financial Reports

No items found.

Press Releases

Lexicon Pharmaceuticals, Inc.

LXRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LXRX